<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554511</url>
  </required_header>
  <id_info>
    <org_study_id>ENKTL-2020</org_study_id>
    <nct_id>NCT04554511</nct_id>
  </id_info>
  <brief_title>Prognostic Nomogram of Extranodal NK/T-cell Lymphoma</brief_title>
  <official_title>Prognostic Nomogram of Extranodal NK/T-cell Lymphoma: A Multi-center Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate prognostic factors for overall survival and explore risk&#xD;
      progression-free survival in ENKTL, and establish a prognostic predictive nomogram for ENKTL&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective cohort study using anonymized information from patients with ENKTL.&#xD;
      The following criteria are required: (1) Patients diagnosed with ENKTL between January 1,&#xD;
      2000 and August 31, 2020; (2) Patients older than 18 years. The pathology of initial&#xD;
      diagnosis was reviewed by designated pathologists.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>Time between the date of diagnosis and any kinds of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 year</time_frame>
    <description>Time between the date of diagnosis and any kinds of death or relapse/progression</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Extranodal NK/T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Training cohort</arm_group_label>
    <description>Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation Cohort</arm_group_label>
    <description>Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020;&#xD;
&#xD;
          2. Patients older than 18 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients newly diagnosed with ENKTL&#xD;
&#xD;
          -  Patients diagnosed between January 1, 2000 and August 31, 2020&#xD;
&#xD;
          -  Patients older than 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who did not have complete clinical information or immunohistochemistry, or&#xD;
             who were lost follow-up immediately after treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Wang</last_name>
    <phone>+862087342462</phone>
    <email>wanghua@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hua wang, MD.</last_name>
      <phone>0086-02087342462</phone>
      <email>wanghua@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 12, 2020</study_first_submitted>
  <study_first_submitted_qc>September 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 12, 2020</last_update_submitted>
  <last_update_submitted_qc>September 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>wanghua</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

